封面
市场调查报告书
商品编码
1410905

核医学成像显影剂的全球市场 - 市场规模(各市场区隔),占有率,法规,偿付,预测(~2033年)

Nuclear Imaging Agents Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

出版日期: | 出版商: GlobalData | 英文 | 订单完成后即时交付

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

本报告提供全球核医学成像显影剂市场相关调查分析,提供各市场区隔的市场规模,市场趋势,竞争情形,COVID-19影响等资讯。

市场模式的主要内容如下列。

已上市的核医学成像显影剂与不断变化的竞争格局

  • 主要的产业趋势考察
  • 核医学成像显影剂市场区隔的年度收益与市场预测(2015年~2033年)
  • 台数,平均销售价格,市场金额相关市场层级的资料

世界,地区,国家层级的市场固有考察

  • 各地区分类的全球趋势之定性市场固有资讯与各国考察
  • 核医学成像显影剂市场SWOT分析
  • 核医学成像显影剂市场竞争动态的考察和趋势

透过掌握包含医疗制度概要的真实整体状况来促进对市场的认识。此外在打入市场部门更提供关于给付原则及法规情势之资讯,使您能够更深入地研究市场动态。

  • 各国医疗制度概要
  • 各国偿付政策
  • 各国医疗技术相关法规形势

对象企业

  • Cardinal Health Inc
  • GE Healthcare
  • Advanced Accelerator Applications SA
  • Bracco Diagnostics Inc
  • Lantheus Holdings Inc
  • 其他

Abstract

Nuclear Imaging Agents Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within Diagnostic Imaging therapeutic area.

The model discusses in detail the impact of COVID-19 on Nuclear Imaging Agents market for the year 2020 and beyond. Nuclear Imaging is a noninvasive medical technique which uses radioactive tracers (generally F-18 Fluorodeoxyglucose) to assess and diagnose bodily functions and diseases. The diseases include cancers, cardiac diseases, gastrointestinal, endocrine and neurological diseases.

Nuclear Imaging Agents's have been classified into Positron Emission Tomography (PET) Systems and Single Photon Emission Computed Tomography (SPECT) Systems. The advanced version of these systems include PET/CT, PET/MRI, SPECT/CT and SPECT/MRI. These systems contain features of both PET and CT/MRI and SPECT and CT/MRI.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Nuclear Imaging Agents and evolving competitive landscape -

  • Insightful review of the key industry trends.
  • Annualized total Nuclear Imaging Agents market revenue by segment and market outlooks from 2015-2033.
  • Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Nuclear Imaging Agents market.
  • Competitive dynamics insights and trends provided for Nuclear Imaging Agents market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Cardinal Health Inc, GE Healthcare, Advanced Accelerator Applications SA, Bracco Diagnostics Inc, Lantheus Holdings Inc and Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the Nuclear Imaging Agents marketplace to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

  • Understand the impact of COVID-19 on Nuclear Imaging Agents market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Nuclear Imaging Agents market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Nuclear Imaging Agents market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Nuclear Imaging Agents market from 2015-2033.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable